Format
Sort by

Send to:

Choose Destination

Results: 5

Related Articles by Review for PubMed (Select 21159366)

1.

A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.

Tait DL, Blessing JA, Hoffman JS, Moore KN, Spirtos NM, Lachance JA, Rotmensch J, Miller DS.

Gynecol Oncol. 2011 Apr;121(1):118-21. doi: 10.1016/j.ygyno.2010.11.027. Epub 2010 Dec 14.

PMID:
21159366
2.

Gemcitabine as a single-agent treatment for ovarian cancer.

Fowler WC Jr, Van Le L.

Gynecol Oncol. 2003 Aug;90(2 Pt 2):S21-3. Review.

PMID:
12928002
3.

[Gemcitabine in advanced stage soft tissue sarcoma: a phase II study].

Amodio A, Carpano S, Manfredi C, Del Monte G, Di Lauro L, Gionfra T, Conti F, Paoletti G, Lopez M.

Clin Ter. 1999 Jan-Feb;150(1):17-20. Review. Italian.

PMID:
10367540
4.

Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option.

Gadducci A, Sergiampietri C, Guiggi I.

Gynecol Endocrinol. 2013 Sep;29(9):811-6. doi: 10.3109/09513590.2013.801446. Epub 2013 Jun 14. Review.

PMID:
23767831
5.

Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature.

Azzoli CG, Miller VA, Ng KK, Krug LM, Hensley ML, O'Reilly EM, Muller RJ, Kris MG.

Am J Clin Oncol. 2003 Jun;26(3):247-51. Review.

PMID:
12796593
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk